You just read:

BioMarin Announces First Patient Dosed in Phase 1/2 Study Evaluating Valoctocogene Roxaparvovec Gene Therapy in Severe Hemophilia A Patients with Pre-existing AAV5 Antibodies

News provided by

BioMarin Pharmaceutical Inc.

May 15, 2018, 08:30 ET